LARS1: A Potential Drug Target and Biomarker (G51520)

Target Name: LARS1

NCBI ID: G51520

LARS1

LARS1: A Potential Drug Target and Biomarker

Introduction

LARS1 (Leucyl-transfer RNA synthetase) is a gene that encodes a protein involved in the process of RNA synthesis. LARS1 is a key player in the regulation of gene expression and has been implicated in various diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD). As a result, LARS1 has emerged as a promising drug target and biomarker for a variety of diseases.

Understanding LARS1

LARS1 is a member of the RNA polymerase II (RNA-II) family, which is responsible for synthesizing long non-coding RNAs (lncRNAs) and small nucleolar RNA (snRNA). RNA-II is a complex enzyme that consists of multiple subunits, including the alpha subunit, beta subunit, gamma subunit, and delta subunit. The alpha subunit is the most well-studied subunit and is responsible for the synthesis of the 28S rRNA, which is the main component of the cell's ribosome.

LARS1 functions as a negative regulator of gene expression by binding to specific target mRNAs and preventing their translation into protein. LARS1 does this by recognizing a specific motif in the 3'-end of the target mRNA. The motif is composed of a leucine residue, which is specific to LARS1, and a series ofU residues, which are also specific to LARS1. When LARS1 binds to a target mRNA, it forms a complex with the alpha subunit of RNA-II and prevents the alpha subunit from binding to the target mRNA . This process inhibits the translation of the target mRNA into protein, which can lead to the suppression of gene expression.

LARS1 and disease

The regulation of gene expression by LARS1 is disrupted in various diseases, including cancer, neurodegenerative diseases, and COPD. LARS1 has been implicated in the development and progression of numerous diseases, including:

1. Cancer: LARS1 has been shown to play a role in the regulation of cancer cell growth and survival. Studies have found that LARS1 is overexpressed in many types of cancer and that its expression is associated with cancer progression.

2. Neurodegenerative diseases: LARS1 is implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that LARS1 is overexpressed in the brains of individuals with these conditions and that its expression is associated with the progression of neurodegeneration.

3. Chronic obstructive pulmonary disease (COPD): LARS1 has been shown to be involved in the regulation of gene expression in the airways of the lungs. Studies have shown that LARS1 is overexpressed in the airways of individuals with COPD and that its expression is associated with the severity of COPD symptoms.

Drug targeting LARS1

The potential drug targets for LARS1 are numerous and range from inhibiting its activity to modifying its expression levels. Some of the most promising drug targets for LARS1 include:

1. Small molecules: Many small molecules have been shown to inhibit the activity of LARS1. These molecules can either inhibit the binding of LARS1 to its target mRNAs or prevent the formation of the LARS1-alpha subunit-LARS1 complex.

2. Antibiotics: Antibiotics have been shown to inhibit the activity of LARS1 in various organisms, including bacteria and fungi. This suggests that LARS1 may be a potential target for antibiotics used to treat bacterial and fungal infections.

3. Molecular chaperones: Molecular chaperones are proteins that help transport and fold small RNAs, including LARS1. inhibitors of molecular chaperones, such as

Protein Name: Leucyl-tRNA Synthetase 1

Functions: Catalyzes the specific attachment of an amino acid to its cognate tRNA in a two step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. Exhibits a post-transfer editing activity to hydrolyze mischarged tRNAs

The "LARS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LARS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets